COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are:
* To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs).
* To evaluate the efficacy of continued skin application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments.
Participants with eligible common warts present will receive YCANTH (VP-102/TO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0/+ 8 days).
If participants still have warts present after 4 additional treatments of YCANTH (VP-102/TO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site:
vesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102/TO-208). Participants may receive treatment until all treatable common warts are clear, up to a maximum of 4 treatment sessions, or until Day 357, whichever occurs first.
Treatment:
For participants with warts present at the time of study entry, the first treatment application may occur on the same day as transition from the parent study. All required parent study assessments must be complete, including the final evaluation of response to treatment (ERT; as defined in Assessments and procedures).
In addition, eligibility for participation in the LTFU study must have been determined, and informed consent/assent for participation in this LTFU study obtained. YCANTH (VP-102/TO-208) will be applied by the Investigator or qualified member of the research team to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. After YCANTH (VP-102/TO- 208) is applied, warts are to be covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and should be removed 24 hours after application of study drug and just before a 24-hour ERT. Before application of study drug, wart paring, if necessary, will be completed with a sharp surgical instrument (eg, scalpel or flexible medical blade) to remove any adherent thick scale from a treatable common wart. Wart paring is required to be performed at any treatment visit when adherent thick scale is present, and the Investigator feels paring can be safely performed. Paring should be conducted by a trained practitioner and in compliance with any local regulations and should be discontinued if it results in punctate bleeding or significant pain. Not all treatable common warts may require paring. If adherent scale is not present, study drug can be applied without paring. The assessment for complete clearance may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated, and the visit will be documented as an Unscheduled Visit. The timing of the next treatment visit will be determined by resolution of the LSRs. The research team will be in contact with the Participant until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. All treatable common warts that are not completely clear should undergo treatment with study drug. Study duration from Days 84, 105, or 147 of the parent study (COVE-2 or COVE-3) through the final EOS visit of this LTFU study (Day 378) is approximately 294 days.

Start Date11 Mar 2026

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+5]

NCT07246590

/ RecruitingPhase 3

COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

Start Date17 Dec 2025

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+4]

JPRN-jRCT2031230204

/ CompletedPhase 1IIT

TO-208 Clinical Pharmacology Study- Open-Label Study to Evaluate the Safety, Efficacy, and Plasma Concentrations of TO-208 in Patients Aged 2 Years and Older with Molluscum Contagiosum -

Start Date27 Jul 2023

Sponsor / Collaborator-

100 Clinical Results associated with Cantharidin

100 Translational Medicine associated with Cantharidin

100 Patents (Medical) associated with Cantharidin

1,194

Literatures (Medical) associated with Cantharidin

01 Apr 2026·BIOCHEMICAL PHARMACOLOGY

Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma

Article

Author: Wang, Yuehua ; Yan, Jia ; Chen, Jie ; Gou, Xianggang ; Wang, Ziyao ; Yuan, Henye ; Wang, Haisheng ; Zhou, Zhongzheng ; Yan, Wei

Cantharidin (CTD) has been traditionally used in Traditional Chinese Medicine (TCM) and exhibits pronounced antitumor activity, particularly in hepatocellular carcinoma (HCC). However, its preclinical translation has been substantially constrained by dose-limiting toxicity. Inspired by traditional Mylabris and Ginseng combinations, we conducted an investigation into the synergistic efficacy of CTD and Ginsenoside-Rg3 (Rg3), one of the most prevalent and bioactive ginsenosides, in combating HCC. We find that CTD/Rg3 co-treatment synergistically suppressed HCC cell proliferation, migration, and invasion. Mechanistically, an integrated multi-omics approach analyses illuminated the involvement of multi-target and multi-pathway mechanisms in CTD/Rg3 combination therapy for HCC. Function enrichment analyses reveal that targets of CTD/Rg3 were significantly associated with metabolic pathways and immune responses. Further screening identified AKR1D1, SLC16A4, and ALDH3B1 as potential drug targets. Subsequent correlation analysis with clinical data from liver cancer patients indicated that AKR1D1 and SLC16A4 were activated, whereas ALDH3B1 was inhibited, during CTD/Rg3 intervention in HCC progression. Molecular docking studies further demonstrated that both CTD and Rg3 bind with high affinity and stability to the active site of ALDH3B1, a molecule associated with immune microenvironment remodeling in HCC. Collectively, our findings demonstrate that CTD/Rg3 combination therapy exerts potent anti-HCC effects through multi-targeted mechanisms. By simultaneously modulating metabolic pathways and immune responses, this strategy represents a novel integrative approach for HCC treatment. These results not only elucidate the molecular basis of CTD/Rg3 efficacy but also provide robust preclinical support for its clinical translation in HCC management.

01 Apr 2026·JOURNAL OF INORGANIC BIOCHEMISTRY

Discovery, crystal structure, anticancer property of the first-row transition metal complexes of norcantharidin (NCTD) as potential inducer of mitochondrial damage

Article

Author: Liu, Li-Min ; Wen, Chang-Chun ; Wei, Hong-Zu ; Liu, Yan-Cheng ; Huang, Yue ; Huang, Yun-Hou ; Liu, Yuan ; Meng, Wei-Ying

Norcantharidin (NCTD) is a structurally modified derivative of cantharidin, which is an active component derived from traditional Chinese medicine (TCM) and exhibiting specific anticancer activity. In this work, four pH-sensitive complexes of NCTD, with cationic 2-aminopyridine (AP) as the counter ion, were successfully synthesized and structurally characterized. The crystal structures resolved by single crystal X-ray diffraction analysis demonstrated that they all formed in complexes with ionic type, 2AP[M(NCTD)₂], (M = Cu, Co, Ni and Mn), composed of the negative divalent six-coordinated species, [M(NCTD)₂]^2-, and two counter cations (AP). Our findings demonstrated that under slightly acidic conditions (pH = 6.6), the decomposition of 2AP[M(NCTD)₂] (M = Cu, Co, Ni, and Mn) led to the release of NCTD and metal ions, which subsequently triggered a Fenton-like reaction co-catalyzed by GSH. They exhibited stronger in vitro anticancer properties than NCTD against a series of typical cancer cell lines tested, with the IC₅₀ values in the range of 12.41-33.43 μM, in which 2AP[Cu(NCTD)₂], showed the best efficacy. In the most sensitive SK-OV-3 cells, 2AP[Cu(NCTD)₂], induced mitochondrial dysfunction by triggering the excessive accumulation of ROS within mitochondria, thereby activating the apoptotic pathway. Meanwhile, 2AP[Cu(NCTD)₂], could obviously arrest the cell cycle at Sub-G₁ phase in SK-OV-3 cells.

01 Mar 2026·PLANT PHYSIOLOGY AND BIOCHEMISTRY

MdPP2AC interacting with MdCLC to mediate ALA-induced salt tolerance in apple

Article

Author: Xiang, Kun ; Wang, Liangju ; Iqbal, Mohsin ; Zhang, Jianting ; Zhou, Jiayi

5-Aminolevulinic acid (ALA) is a plant growth regulator that enhances salt tolerance, yet the underlying mechanisms remain unclear. In this study, we investigated the function and molecular mechanism of the Protein Phosphatase 2A (PP2A) catalytic subunit MdPP2AC in ALA-induced salt tolerance in detached leaves, calli, and rooted plantlets of 'Gala' apple (Malus × domestica). Results showed that pretreatment with ALA before NaCl stress significantly alleviated NaCl-induced damage, enhanced antioxidant enzyme activities, and improved chloride (Cl^-) interception in the roots with less transport to the aboveground. Further analysis revealed that the PP2A activity and MdPP2AC expression were induced by NaCl and further by ALA. Functional studies showed that overexpressing (OE)-MdPP2AC enhanced salt tolerance, whereas RNA interference (RNAi)-MdPP2AC or application of cantharidin (CT, a specific inhibitor of PP2A activity) compromised salt tolerance, but exogenous ALA mitigated CT-aggravated salt injury. Yeast two-hybrid (Y2H), bimolecular fluorescence complementation (BiFC), luciferase complementation imaging (LCI), sequence truncation and site-directed mutagenesis assays confirmed that MdPP2AC can interact with the chloride channel protein MdCLC-c2, and the C-terminal Glu⁶⁸⁴ residue of MdCLC-c2 is indispensable for the molecular interaction and Cl^- transport activation. Function identification with Δgef1 mutant yeast showed that MdCLC-c2 transformation promoted intracellular Cl^- accumulation as well as cell salt tolerance, and the effects were further promoted by MdPP2AC transformation and exogenous ALA. Collectively, we propose that MdPP2AC mediates ALA-induced salt tolerance in apple by interacting with MdCLC-c2, which promotes Cl^- sequestration into root vacuoles with less transport to the aboveground, thus maintaining Cl^- homeostasis at the cellular and plant levels. These findings reveal a novel mechanism whereby PP2AC modulates chloride channel function to maintain ion homeostasis within the ALA signaling pathway, providing critical insights into ALA-mediated apple salt tolerance.

110

News (Medical) associated with Cantharidin

22 hours ago

·www.biospace.com

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, , or by clicking here . A replay of the webcast will be archived on Verrica’s website for 90 days following the event. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

10 Apr 2026

·www.biospace.com

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica’s novel oncolytic peptide for the treatment of basal cell carcinoma. The data will be presented at the upcoming 2026 Society for Investigative Dermatology (SID) Annual Meeting, which will take place from May 13-16, 2026, in Chicago, Illinois. Presentation Details: Title: “VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors” Poster Number: LB1190 Category: Non-Melanoma Cancers and UV Biology/Injury Poster Session Dates and Time: Friday, May 15, 2026 (4:30 pm – 6:00 pm) Location: (Salons B,C,D - Lower Level, Hilton Chicago) About VP- 315 (ruxotemitide) VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials. About Basal Cell Carcinoma Basal cell carcinoma is the most common form of cancer in the U.S., and incidence is rising worldwide. There are approximately 3.6 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options. Basal cell carcinoma is generally treated with invasive surgery to remove the tumor, which can cause pain, infection, bleeding and scarring. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancer. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the clinical development and benefits of Verrica’s product candidates, including VP-315. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

License out/inPhase 2ImmunotherapyDrug Approval

06 Apr 2026

·www.biospace.com

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026 Event details: Date: Wednesday, April 15, 2026 Time: 3:00pm ET Location: Virtual Participants may access a live webcast of the event by clicking the link here . The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at . A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event. About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancer. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit . FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

License out/inDrug Approval

100 Deals associated with Cantharidin

External Link

KEGG	Wiki	ATC	Drug Bank
D11745	Cantharidin	D11AF	DB12328

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Molluscum Contagiosum	United States	Verrica Pharmaceuticals, Inc.	21 Jul 2023
Condylomata Acuminata	China	Hainan Huiyuantang Pharmaceutical Co Ltd	10 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plantar wart	Phase 3	United States	Verrica Pharmaceuticals, Inc.	17 Dec 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2025	Phase 3	Molluscum Contagiosum	303	TO-208	slxkrvdtmh(udqbwgsdds) = pvqcqiouzg femrvdqfkg (hgjomqljcb ) View more	Positive	07 Mar 2025
				Placebo	slxkrvdtmh(udqbwgsdds) = nqjhekkemk femrvdqfkg (hgjomqljcb ) View more
GlobeNewswire Manual	Phase 3	Molluscum Contagiosum	-	TO-208	sglgkxxtsd(kaufonuuxl) = statistically significant versus placebo phwebuifqc (naoatxpoan )	Positive	15 Dec 2023
				Placebo
NCT03377803 \| NCT03377790 (FDA) Manual	Phase 3	Molluscum Contagiosum	528	YCANTH (Trial 1)	sjfbfudrlp(rqerjldnkn) = mnhjqbnnws pkhflokbev (jakosdbvje ) View more	Positive	21 Jul 2023
				Vehicle (Trial 1)	sjfbfudrlp(rqerjldnkn) = wkzvasaryk pkhflokbev (jakosdbvje ) View more
NCT03377803 (CAMP-2, CTgov)	Phase 3	Molluscum Contagiosum	262	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	ptfcejxjax = tbuxhcfkhw otdjkiopzo (nscpgfyjiw, zjkifybflc - bfqdrfpirc) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	ptfcejxjax = klhzgsrjok otdjkiopzo (nscpgfyjiw, hgouopawtz - xwndfeiavp) View more
NCT03377790 (CAMP-1, CTgov)	Phase 3	Molluscum Contagiosum	266	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	qwlchoqdar = vzctzesahm omhxlvtlxl (gwivxydmow, otikguljzw - etmllkauhe) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	qwlchoqdar = hkmwhzrpas omhxlvtlxl (gwivxydmow, widilrbchu - mfheaynqcw) View more
NCT03981822 (Pubmed \| Am J Clin Dermatol) Manual	Phase 2	Condylomata Acuminata	-	VP-102	cbbfmvbtff(qjpbizlzia) = cxrekwdnwp xzocynobwk (nuxmyztugs ) View more	Positive	01 Nov 2021
				Placebo	cbbfmvbtff(qjpbizlzia) = ehnvqrwcfp xzocynobwk (nuxmyztugs ) View more
NCT03487549 (COVE-1, Pubmed) Manual	Phase 2	Warts	56	VP-102 (Cohort 1)	dlgbahkofs(dfkddygpnc) = zzyvburbff ujkjrfoivo (ilheajlhtd )	Positive	01 Oct 2021
				VP-102 (Cohort 2)	dlgbahkofs(dfkddygpnc) = mkqhoizwdn ujkjrfoivo (ilheajlhtd )
NCT03981822 (CARE-1, CTgov)	Phase 2	Condylomata Acuminata	105	VP-102 (Part B Pooled With Part A: VP-102 6-hour)	tjanzqhawg: P-Value = 0.0048 View more	-	22 Sep 2021
				Placebo (Part B Pooled With Part A: Placebo 6-hour)
NCT03487549 (COVE-1, CTgov)	Phase 2	Warts	56	VP-102 (Cohort 1)	dxfmyyxkjv = jgcvfgghvd wvozyatotl (ibarvypaxz, nrwqjikbkd - inkrimcdgh) View more	-	01 Sep 2021
				VP-102 (VP-102 - Cohort 2)	mrzxarakvm = lceztezznv cnuhwvzehv (tqksezvpdo, xkufrxemde - kgoluepcek) View more
NCT03186378 (CTgov)	Phase 2	Molluscum Contagiosum	33	VP-102 with applicator (Exposure Group)	udagtfzvmi = hpodonljpq srzbetolal (zoivqkhgyl, qobbnqfoju - yknurucrlz) View more	-	09 Aug 2021
				VP-102 with applicator (Standard Group)	udagtfzvmi = flwyulbjes srzbetolal (zoivqkhgyl, mzkupehucs - hhnukzdbcn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cantharidin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation